|
medpundit |
||
 |
 |
|
Wednesday, October 09, 2002The findings stemmed out of research into the contract signed by Nancy Olivieri, a University of Toronto hematologist at the Hospital for Sick Children. In 1996, when Olivieri was conducting clinical trails on the effectiveness of a drug forthalassemia patients, she discovered the drug was not effective in some patients and might even cause liver damage. Apotex, the company which manufactured the drug and sponsored Olivieri's work, terminated the trials and issued a legal warning to prevent Dr. Olivieri from disclosing the risks to patients or publishing her findings. Yet another reason why publishing favors positive outcomes and why authors of papers put the best possible spin on the most marginal of findings. (And why you can't assume that papers speak the unadulterated truth, even if they appear in prestigious journals.) posted by Sydney on 10/09/2002 08:23:00 AM 0 comments 0 Comments: |
|
